SCHAUMBURG, Ill., March 13 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company today announced that it has launched Cefazolin for injection, USP, an essential antibiotic used to treat serious infections. Sagent's Cefazolin for injection will be available in 1g single dose vials and 10g pharmacy bulk package vials. According to IMS data, sales of Cefazolin in the United States in 2006 were approximately $69 million.
The introduction of Cefazolin for injection marks the second product launch in three months from Sagent's pipeline of more than 200 products. The launch of Cefazolin for injection follows Sagent's December 2007 introduction of the first full-line of latex-free, multi-source prefilled, ready-to-use, 6 mg and 12 mg, adenosine syringes in the market. Sagent will begin marketing and shipping Cefazolin immediately.
"The launch of Cefazolin, the first product to emerge from our extensive anti-infective pipeline, marks further progress toward Sagent's ultimate goal of becoming a leader in the injectables marketplace," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "This product provides our customers another sourcing option for this important antibiotic and, as with all Sagent products, offers enhanced labeling intended to optimize product safety and increase efficiency in the hospital."
Cefazolin for injection, USP, is the generic equivalent of
GlaxoSmithKline's ANCEF(R), an antibiotic used to treat bacterial
infections. Cefazolin for injection, USP, is indicated for serious
infections such as those of the respiratory, biliary and urinary tracts,
skin and skin structure infections, bone and joint infections, and other
infections caused by various strains of streptococci. Prophylactic
Cefazolin for injection, USP, preoperative, intraopertative and
postoperative administration can be effective in reducing the incidence of
|SOURCE Sagent Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved